Financing led by RA Capital Management and co-led by RTW Investments and Janus Henderson Investors Proceeds to further advance the company's differentiated radiopharmaceuticals pipeline, including its first-in-class Nectin-4-targeted miniprotein radioconjugate Company will present three abstracts, including an oral presentation, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics , October 23-25, 2024 BOSTON , Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. The financing was led by RA Capital Management, and co-led by RTW Investments and Janus Henderson Investors.
A select syndicate of additional new investors joined the financing, including funds and accounts advised by T. Rowe Price Associates, Inc., Avidity Partners, and an undisclosed life sciences-focused investment fund.
All existing institutional investors participated, as well as existing strategic investors Bristol Myers Squibb, Eli Lilly and Company, and MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc. Aktis Oncology also announced that three abstracts, including one oral presentation, have been accepted for presentation at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Can.
